PTX-COVID19-B

BIOLOGICAL4 trials

Sponsors

Providence Therapeutics Holdings Inc., Everest Medicines (Singapore) Pte. Ltd.

Conditions

Covid19 VaccineSARS-CoV-2 Infection

Phase 1

PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64

CompletedNCT04765436

Providence Therapeutics Holdings Inc.Covid19 Vaccine

Start: 2021-01-14End: 2022-03-30Updated: 2022-04-25

Phase 2

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

CompletedNCT05175742

Providence Therapeutics Holdings Inc.Covid19 Vaccine

Start: 2021-08-17End: 2023-03-29Updated: 2023-04-07

Phase 3

Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older

Everest Medicines (Singapore) Pte. Ltd.SARS-CoV-2 Infection

Start: 2023-02-03End: 2023-10-18Target: 450Updated: 2022-09-09

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

WithdrawnNCT05534048

Everest Medicines (Singapore) Pte. Ltd.SARS-CoV-2 Infection

Start: 2023-02-03End: 2023-12-20Updated: 2026-09-11

Related Papers

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Scientific Reports2024-03-045 citations

Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Scientific Reports2023-05-267 citations